Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Diabetes Mellitus and HbA1c Levels Associated with High Grade Prostate Cancer

  • Ozbek, Emin (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Otunctemur, Alper (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Dursun, Murat (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Sahin, Suleyman (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Besiroglu, Huseyin (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Koklu, Ismail (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Erkoc, Mustafa (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Danis, Eyyup (Okmeydani Training and Research Hospital, Department of Urology) ;
  • Bozkurt, Muammer (Okmeydani Training and Research Hospital, Department of Urology)
  • Published : 2014.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Pirpose: The aim of this study to analyze the association between history of diabetes mellitus (DM) with risk of prostate cancer (PCa) and cancer grade among men undergoing radical prostatectomy for PCa. Materials and Methods: 50 patients with DM and 50 patients without DM who undervent radical prostatectomy (RP) were included in the study. Age at biopsy, height, weight, digital rectal examination (DRE), pre-biopsy PSA levels, prostate volume, histopathologic diagnosis after surgery and gleason scores were collected data from all patients. Histologic material obtained at biopsy was given a Gleason score; tumours with a Gleason score ${\geq}7$ were considered high grade and <7 were considered low grade. Results: The mean age at the time of biopsy was 63.7 in patients with DM and 61.6 in patients without DM. Diabetic men had significantly lower PSA levels (p=0.01). Mean PSA level $7.04{\pm}2.85$ in patients with DM and $8.7{\pm}2.86$ in patients without DM, respectively. Also, diabetic men had higher RP tumor grade than men without DM (p=0.04). We found that HbA1c levels were higher in patients who have high grade prostate cancer (p<0.05). Conclusions: Diabetic men undergoing RP have lower PSA levels and have significantly higher grade PCa. We must be careful for screening PCa in patients with DM. Although the patients had lower PSA levels, they might have high grade disease.

Keywords

References

  1. Abdollah F, Briganti A, Suardi N, et al (2011). Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis, 14, 74-8. https://doi.org/10.1038/pcan.2010.41
  2. Antonelli JA, Jones LW, Banez LL, et al (2009). Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol, 182, 2226-31. https://doi.org/10.1016/j.juro.2009.07.028
  3. Avci CB, Harman E, Dodurga Y, et al (2013). Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev, 14, 765-8. https://doi.org/10.7314/APJCP.2013.14.2.765
  4. Balasubramaniam G, Talole S, Mahantshetty U, Saoba S, Shrivastava S (2013). Prostate cancer: a hospital-based survival study from Mumbai, India. Asian Pac J Cancer Prev, 14, 2595-8. https://doi.org/10.7314/APJCP.2013.14.4.2595
  5. Berger AP, Deibl M, Halpern EJ, et al (2005). Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia, 48,784-9. https://doi.org/10.1007/s00125-005-1678-6
  6. Bonovas S, Filioussi K, Tsantes A (2004). Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47, 1071-8.
  7. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR (2005). History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control, 16, 789-97. https://doi.org/10.1007/s10552-005-3301-z
  8. Demir U, Koehler A, Schneider R, et al (2014). Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells. BMC Cancer. 31, 14-52.
  9. Epstein JI, Allsbrook WC Jr, Amin MB, et al (2005). The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol, 29, 1228-42. https://doi.org/10.1097/01.pas.0000173646.99337.b1
  10. Fall K, Garmo H, Gudbjornsdottir S, et al (2013). Diabetes mellitus and prostate cancer risk; a nationwide casecontrol study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev, 22, 1102-9. https://doi.org/10.1158/1055-9965.EPI-12-1046
  11. Fowke JH, Motley SS, Cookson MS, et al (2007). The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis, 10, 137-42. https://doi.org/10.1038/sj.pcan.4500924
  12. Fukushima H, Masuda H, Kawakami S, et al (2012). Effect of diabetes mellitus on high-grade prostate cancer detection among Japanese obese patients with prostate-specific antigen less than 10ng/mL. Urology, 79, 1329-35. https://doi.org/10.1016/j.urology.2012.01.070
  13. Gong Z, Neuhouser ML, Goodman PJ, et al (2006). Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev, 15, 1977-83. https://doi.org/10.1158/1055-9965.EPI-06-0477
  14. Hammarsten J, Hogstedt B (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol, 39, 151-8. https://doi.org/10.1159/000052430
  15. Hong SK, Oh JJ, Byun SS, et al (2011). Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (_12)-core prostate biopsy. Prostate, 72, 51-7.
  16. Jayachandran J, Aronson WJ, Terris MK, et al (2010). Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev, 19, 9-17. https://doi.org/10.1158/1055-9965.EPI-09-0777
  17. Kang J, Chen MH, Zhang Y, et al (2012). Type of diabetes mellitus and the odds of Gleason score 8-10 prostate cancer. Int J Radiat Oncol Biol Phys, 82, 463-7. https://doi.org/10.1016/j.ijrobp.2010.10.001
  18. Kasper JS, Giovannucci E (2006). A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 15, 2056-62. https://doi.org/10.1158/1055-9965.EPI-06-0410
  19. Kim H, Presti JC Jr, Aronson WJ, et al (2010). Glycemic control and prostate cancer progression: results from the search database. Prostate, 70, 1540-6. https://doi.org/10.1002/pros.21189
  20. Leitzmann MF, Ahn J, Albanes D, et al (2008). Diabetes mellitus and prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control, 19, 1267-76. https://doi.org/10.1007/s10552-008-9198-6
  21. Long XJ, Lin S, Sun YN, Zheng ZF (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis. Asian Pac J Cancer Prev, 13, 4097-100. https://doi.org/10.7314/APJCP.2012.13.8.4097
  22. Lu K, Song XL, Han SL, Wang CH, Zhong N, Qi LF (2014). Potential study perspectives on mechanisms and correlations between adiposity and malignancy. Asian Pac J Cancer Prev, 15, 1057-60. https://doi.org/10.7314/APJCP.2014.15.2.1057
  23. McGrowder DA, Jackson LA, Crawford TV (2012). Prostate cancer and metabolic syndrome: is there a link? Asian Pac J Cancer Prev, 13, 1-13. https://doi.org/10.7314/APJCP.2012.13.1.001
  24. Moreira DM, Anderson T, Gerber L, et al (2011). The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control, 22, 977-83. https://doi.org/10.1007/s10552-011-9770-3
  25. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H (2009). Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev, 18, 1350-6. https://doi.org/10.1158/1055-9965.EPI-08-0794
  26. Oliver SE, Gunnell D, Donovan J, et al (2004). Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer, 108, 887-92. https://doi.org/10.1002/ijc.11631
  27. Pierce BL, Plymate S, Ostrander EA, Stanford JL (2008). Diabetes mellitus and prostate cancer risk. Prostate, 68, 1126-32. https://doi.org/10.1002/pros.20777
  28. Turgutalp K, Ozhan O, Helvaci I, et al (2013). Serum levels of cancer biomarkers in diabetic and non-diabetic proteinuric patients: a preliminary study. Clin Chem Lab Med, 51, 889-95.
  29. Van Praet C, Libbrecht L, D'Hondt F, et al (2013). Agreement of gleason score on prostate biopsy and radical prostatectomy specimen: is there improvement with increased number of biopsy cylinders and the 2005 revised gleason scoring? Clin Genitourin Cancer, [Epub ahead of print].
  30. Vigneri P, Frasca F, Sciacca L, et al (2009). Diabetes and cancer. Endocr Relat Cancer, 16, 1103-23. https://doi.org/10.1677/ERC-09-0087
  31. Wallner LP, Morgenstern H, McGree ME, et al (2011). The effects of type 2 diabetes and hypertension on changes in serum prostate specific antigen levels: results from the Olmsted county study. Urology, 77, 137-41. https://doi.org/10.1016/j.urology.2010.07.516
  32. Waters KM, Henderson BE, Stram DO, et al (2009). Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol, 169, 937-45. https://doi.org/10.1093/aje/kwp003
  33. Werny DM, Saraiya M, Gregg EW (2006). Prostate-specific antigen values in diabetic and nondiabetic US men, 2001- 2002. Am J Epidemiol, 164, 978-83. https://doi.org/10.1093/aje/kwj311
  34. Woo HY, Park H, Kwon MJ, Chang Y, Ryu S (2012). Association of prostate specific antigen concentration with lifestyle characteristics in Korean men. Asian Pac J Cancer Prev, 13, 5695-9. https://doi.org/10.7314/APJCP.2012.13.11.5695
  35. Wu C, Moreira DM, Gerber L, et al (2011). Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis, 14, 326-31. https://doi.org/10.1038/pcan.2011.28
  36. Xu H, Mao SH, Ding GX, Ding Q, Jiang HW (2013). Diabetes mellitus reduces prostate cancer risk - no function of age at diagnosis or duration of disease. Asian Pac J Cancer Prev, 14, 441-7. https://doi.org/10.7314/APJCP.2013.14.1.441

Cited by

  1. Prostate-Specific Antigen Levels in Relation to Background Factors: Are there Links to Endocrine Disrupting Chemicals and AhR Expression? vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6121
  2. Poor Glycemic Control of Diabetes Mellitus Is Associated with Higher Risk of Prostate Cancer Detection in a Biopsy Population vol.9, pp.9, 2014, https://doi.org/10.1371/journal.pone.0104789
  3. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study vol.20, pp.3, 2017, https://doi.org/10.1038/pcan.2017.14
  4. Diabetes-induced hyperglycemia impairs male reproductive function: a systematic review vol.24, pp.1, 2017, https://doi.org/10.1093/humupd/dmx033